Recursion Pharmaceuticals Inc. (RXRX)

A. Company Overview

Recursion Pharmaceuticals Inc. embodies a pioneering paradigm in the biotechnology sector, specifically focusing on industrializing drug discovery through innovative technology. Founded in 2013, the company seeks to decode complex biological processes to enhance and expedite the development of new drugs. By utilizing a comprehensive framework, known as the Recursion Operating System (OS), the organization leverages an extensive collection of over 50 petabytes of proprietary data to innovate therapeutic insights.

The Recursion OS integrates a diverse array of physical laboratory techniques (wet-lab) with advanced computational tools (dry-lab). This combination enables the mapping and navigation of extensive biological and chemical relationships, fostering an iterative experimental approach with the goal of discovering more effective treatments across various therapeutic areas, particularly in precision oncology and rare genetic diseases.

B. Business Overview

Recursion's mission revolves around advancing a technology-driven approach to understand biology, with a vision centered on providing better access to medication at reduced costs. This integrates both biological and patient-centric data streams. Recursion emphasizes three primary value drivers in its business model:

1. Internal Pipeline: Recursion manages a robust pipeline of clinical and preclinical programs designed to address unmet medical needs in various populations, particularly focusing on precision oncology and rare diseases. Several programs are projected to reach a market potential exceeding $1 billion in annual sales.
2. Transformational Partnerships: Collaborations with leading biopharmaceutical and technological institutions enhance Recursion's capabilities in mapping complex biological areas and discovering novel therapeutic targets. Notably, partnerships with organizations such as Roche and Genentech facilitate the advancement of promising drug candidates through pooled expertise and resources.
3. Industry-Leading Dataset: The company's wealth of high-quality, fit-for-purpose biological and chemical data underpins its drug discovery process. This dataset is purposefully designed to harness computational tools and expedite value realization through the internal pipeline and partnerships.

C. Key Achievements in 2023

In 2023, Recursion showcased significant advancement in its pipeline with numerous clinical developments:

• Clinical Programs: The company moved forward with five clinical-stage projects, anticipating multiple data readouts, including important studies for treatment protocols in conditions like cerebral cavernous malformation (CCM) and familial adenomatous polyposis (FAP).
• Phase 1 Studies: Successful completion of Phase 1 trials for REC-3964 highlighted its safety, paving the way for future Phase 2 studies targeting recurrent Clostridioides difficile infections.
• Partnership Development: The ongoing collaboration with Roche was revisited with Roche exercising its option to advance a partnership project in gastrointestinal oncology, underlining the fruitful collaboration facilitating new drug development.

D. Recursion Operating System (OS)

The Recursion OS serves as the backbone of the company's operations, comprising an integrated system of wet-lab and dry-lab components designed to streamline the entire drug discovery process.

Automation and Workflow

The OS employs advanced automation techniques to manage repetitive laboratory workflows, yielding vast quantities of experimental data with minimal human interference. Automated platforms ensure consistency, speed, and precision in data generation, allowing for rapid iteration and insights across various stages of drug discovery. This includes:

• LOWE (Large Language Model-Orchestrated Workflow Engine): This interface connects various components of Recursion's OS, enabling researchers to carry out complex sequencing and experimental protocols via simple natural language commands.
• High-Throughput Systems: Systems designed for high-content microscopy, CRISPR genome editing, and in vivo study data collection allow for the creation of expansive datasets, which are crucial for training machine learning models to derive predictive insights.

Data Universe

The datasets within the Recursion OS include:

• Phenomic Data: Generated through high-dimensional biological investigations, enabling the capture of cellular imaging and changes in morphology.
• Transcriptomic and InVivomics Data: These datasets complement the phenomic data by adding layers of biological and chemical context, enhancing the understanding of mechanisms underlying drug responses.

The integration of diverse datasets facilitates the mapping and navigation of trillions of relationships, thus identifying potential therapeutic targets and accelerating the drug development cycle.

E. Clinical Pipeline

Recursion maintains a broad portfolio of clinical programs addressing various critical health conditions, notably:

• REC-994: Currently in Phase 2 trials for treating CCM, a rare condition lacking approved therapies.
• REC-2282: Targeting neurofibromatosis type 2 (NF2), this HDAC inhibitor is in a Phase 2/3 study, demonstrating strong preliminary efficacy in patients.
• REC-4881: With several indications including familial adenomatous polyposis and cancers associated with AXIN1 or APC mutations, this MEK inhibitor is currently progressing through various clinical phases.

The company’s approach emphasizes understanding the underlying biology of diseases to develop insightful therapeutic interventions.

F. Partnerships and Collaborations

Strategic collaborations are integral to Recursion’s operational strategy. Partnerships with biopharma giants like Roche, Bayer, and tech entities such as NVIDIA bolster the company’s research capabilities and provide extensive datasets instrumental in predictive modeling for drug discovery.

Strategic Collaborations

1. Roche and Genentech: This collaboration focuses on the discovery and development of novel therapeutic small molecule programs, with significant funding and resource allocation enabling comprehensive research efforts.
2. NVIDIA: Aiming to harness cutting-edge supercomputing capabilities for developing foundation models in pharmacology, this collaboration has the potential to enhance the computational power available for ongoing data analysis.
3. Tempus: This partnership facilitates access to extensive oncology patient data, fostering the development of causal AI models aimed at discovering novel therapeutic hypotheses.
4. Enamine: Collaborating in developing enriched compound libraries to revolutionize the drug discovery process, enhancing the utility of Recursion’s expansive predictive models.